Bio + Health

a16z’s Guide to How Science Becomes Engineering

a16z editorial Posted January 9, 2020

a16z’s Guide to How Science Becomes Engineering Table of Contents

Editor’s Note: This post first appeared as an edition of the a16z Bio Newsletter. To sign up for this and other a16z newsletters, please visit our subscription center here.

Biology today is where information technology was 50 years ago. Our ability to engineer biology will change how we diagnose, treat, and manage disease; create new medicines and therapeutics; how we access, pay for, and deliver healthcare… and how it will eat, er, change our world (here’s our manifesto). Here’s our guide to the why, what, where, and how science is becoming engineering.

Foundations and frameworks

  • Eroom’s Law Information technology has Moore’s Law, but bio has had the reverse (for worse). To us, that means opportunity — this video shares why.
  • AI is driving discovery Even how we do science itself is changing, thanks in large part to AI industrializing knowledge discovery, as described in this video.
  • Programming medicine From the cell to the gene to the living microbiome, our ability to “program” medicine changes how we design drugs, therapies, and ways to treat disease. This presentation shares the evolution of what medicine is becoming.

Tools and Knowhow

  • How to engineer biology Just because biology involves complex systems doesn’t mean we can’t design and engineer the tools we use to manage it; borrowing from engineering, here are some key principles.
  • And how to reverse engineer it, too The idea of reverse engineering biology seems like a paradox; how could we ever reverse engineer anything for which we didn’t “invent” the original technology? We need key tools and concepts from both worlds.
  • Wherefore synthetic biology? Synthetic biology — aka “synbio” — is arguably the OG field where engineering and bio first met. How did the field come to be, where are we today, and where are we going? Listen to this podcast with one of the pioneers of the field.
  • So you wanna build a software company in healthcare? It’s not just theories but putting it all into practice… and then on top of it, building a company that can scale. Why is this so damn hard? This podcast shares specific things healthcare founders can and should do.

Broader Landscape and Systems

  • Pharma: This wide-ranging conversation with the CEO of Novartis debates what’s science vs science fiction when it comes to science becoming engineering — how do these questions play out in a huge company within a complex industry?
  • Manufacturing: How will new kinds of medicines be manufactured, scaled, delivered? Field notes from the Cell and Gene Meeting on the Mesa on how entrepreneurs, biopharma leaders, and contract organizations are doubling down and overcoming challenges in getting new medicines to the most patients.
  • Care Delivery: Not only is software eating care delivery (this video shows where and why), new technologies like pharma delivery drones and others are starting to solve the last mile.
  • Policy: With all the recent statements against germline editing and regulatory moves around gene therapy kits and more (and meanwhile, clinical trials for CRISPR are finally coming of age) — what’s hype, what’s real; where are we now?
  • Innovation ecosystems: There used to be two very different Boston and Silicon Valley company building models for bio/tech. Now there’s a new breed of multidisciplinary founders — and an entirely new model for the next generation of bio startups: “born in the wild vs. bred in captivity”.
Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.